Screener / SEC EDGAR /CIK 0000730272 /10-K filed Feb 26, 2026, compared with Mar 14, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Repligen Corp RGEN

Compare with peers Embed
The 10-K against last year's

181 changes: 45 added, 51 removed, 81 reworded, 4 quiet changes

10-K Feb 26, 2026 vs Mar 14, 2025

10-K 0001193125-26-076528 (Feb 26, 2026) vs 10-K 0000950170-25-038999 (Mar 14, 2025) Not compared: Legal Proceedings, Accounting Policies.

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

177 paragraphs · 28 new · 80 reworded · 21 gone · 10-K Feb 26, 2026 against Mar 14, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 111 · 50% changed Every version of it
As discussed below in Part II, Item 9A, “Controls and Procedures,” 3.Irrespective of this report, we have identified material weaknesses in our internal control over financial reporting related to (i) controls related to revenue recognition specific to the evaluation effects of accounting for contract terms, (ii) information technology (“IT”) the IT general controls for information systems that are relevant to the preparation of our financial statements, and (iii) deficiencies, management did not perform certain business process-level controls related to inventory valuation and the financial statement close process either in a timely manner or with an appropriate precision threshold. As a result of these material weaknesses, our management concluded that our internal control over financial reporting was not effective as of December 31, 2024.
Paragraph 166 · 50% changed Every version of it
We consider trade secrets, know-how and other forms of market protection to be among the most important elements of our proprietary position, in particular, as it relates to many of the products that currently account for a majority of our revenue. We also own or have exclusive rights to U.S. patents and U.S. pending patent applications as well as corresponding foreign patents and patent applications. We Though we continue to actively and selectively pursue patent protection and seek to expand our patent estate, particularly for our products currently in development, and protection, we cannot be sure guarantee that any patent applications that we will file in the future or that any currently pending applications will issue on a timely basis, if ever. We cannot be certain that we were the first to conceive the invention(s) described by each of our pending patent applications or that we were the first to file patent applications for such invention(s). Even if patents are issued, the degree of protection afforded by such patents will depend upon the:
Paragraph 138 · 47% changed Every version of it
The efforts of Health care reform measures could adversely affect our business. Efforts by governmental and third-party payors to contain or reduce the costs of health care costs may adversely affect the business and financial condition of negatively impact pharmaceutical and biotechnology companies, including ours. Specifically, Legislative and regulatory proposals in both the United States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals abroad continue to change the seek changes to health care system in ways systems that could affect our ability to sell our products profitably. For the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (together, the “ACA”), substantially changed the way health care is financed by both governmental and private insurers. The ACA and other federal and state proposals and health care reforms could limit the prices that can be charged for the products we develop and may limit our commercial opportunity.
Paragraph 136 · 45% changed Every version of it
Investor advocacy groups, certain institutional investors, investment funds, other market participants and other stakeholders have focused increasingly on the Environmental, Social and Governance (“ESG”) practices of companies, including those associated with climate change. These parties have placed increased importance on the importance on the implications of the social cost of their investments. If our ESG practices do not meet investor or other industry stakeholder expectations and standards, which continue to evolve, our reputation and associate employee retention may be negatively impacted based on an assessment of our ESG practices. impacted. Any sustainability disclosures we make may include our policies and practices on a variety of social and ethical matters, including corporate governance, environmental compliance, employee health and safety practices, safety, human capital management, product quality, supply chain management, and workforce inclusion. It is possible that stakeholders Stakeholders may not be satisfied with our ESG practices or the speed pace of their adoption, or that we may not sufficiently fail to communicate our them effectively. Compliance with emerging ESG practices sufficiently to stakeholders. We regulations, including the EU requirements, could also incur result in additional costs and require additional resources to monitor, report, resource commitments for monitoring, reporting, and comply with various ESG practices. In addition, investors assurance. Investors may decide to also refrain from investing in us as a result of based on their assessment of our approach to and consideration of the ESG factors. approach.
Paragraph 171 · 44% changed Every version of it
Patents that may be granted to us in Relatedly, certain foreign countries patent applications may be subject to opposition proceedings brought by third parties or result in suits by us, parties, which may be costly and result in adverse consequences for us.
Paragraph 69 · 40% changed Every version of it
In July 2023, our Board of Directors (“Board”) authorized the Company's management team to undertake we undertook restructuring activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations (the “Restructuring Plan”). As part of operations. We may need to undertake another organizational restructuring in the Restructuring Plan, we consolidated a portion of our manufacturing business between certain U.S. locations and reduced our headcount. future. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our any future restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the Restructuring Plan, a restructuring, our operating results and financial condition could would be adversely affected. Furthermore, the Restructuring Plan our restructuring plan may be disruptive to our operations. Further restructuring and cost-cutting activities may be required and For example, any future headcount reductions could yield unintended consequences and costs, unanticipated consequences, such as a reduction increased difficulties in morale among our remaining employees, adverse effects to our reputation as both an employer and with respect to customers, the loss of institutional knowledge and expertise, and increased likelihood of turnover of key members of management and employees, all of which can impede our ability to successfully implement implementing our business strategy, and consequently, including retention of our business, financial condition, and results of operations remaining employees. A future restructuring may lead to employee litigation related to the headcount reduction, which could be materially costly and adversely affected. prevent management from fully concentrating on the business.
Paragraph 112 · 39% changed Every version of it
As discussed below in Part II, Item 9A, “Controls and Procedures,” of in this report, we have identified Annual Report on Form 10-K, the material weaknesses in our internal control over financial reporting related to (i) controls weakness related to revenue recognition specific to has been remediated and no longer exists as of December 31, 2025. However, the evaluation of accounting for contract terms, (ii) information technology (“IT”) material weaknesses associated with IT general controls for information systems that are relevant to the preparation of our financial statements, and (iii) business process-level process controls related to inventory valuation and the financial statement close process either in a timely manner or with an appropriate precision threshold. As a result were not remediated as of December 31, 2025. Based on these unremediated material weaknesses, our the Company’s management concluded that our at December 31, 2025, the Company’s internal control over financial reporting was not effective as of December 31, 2024. effective.
Paragraph 163 · 39% changed Every version of it
We consider trade secrets, know-how and other forms of market confidentiality protection to be among the most important elements of our proprietary position, in particular, position as it relates to many of the products that currently account for a majority of our revenue. We also own or have exclusive rights to U.S. a global portfolio of patents and U.S. pending patent applications as well as corresponding foreign patents and patent applications. We continue to actively and selectively pursue patent protection and seek to expand Our success depends, in part, on our patent estate, particularly for our products currently in development, and we cannot be sure that any patent applications that we will file in the future or that any currently pending applications will issue on a timely basis, if ever. We cannot be certain that we were the first to conceive the invention(s) described by each of our pending patent applications or that we were the first to file patent applications for such invention(s). Even if patents are issued, the degree of protection afforded by such patents will depend upon the: ability to:

MD&A

71 paragraphs · 17 new · 42 reworded · 30 gone · 10-K Feb 26, 2026 against Mar 14, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 33 · 49% changed
In 2025, R&D expenses increased $0.5 $11.0 million, or 1.1%, during 2024, 25.4%, compared to 2023. 2024. The increase during the periods in R&D costs is primarily due to a $1.8 million increase driven by the 908 Devices PAT Portfolio and Tantti acquisitions, which have been included in employee-related costs, partially offset by a decrease in product development costs our consolidated results of $1.4 million. operations since the acquisition dates of March 2025 and December 2024, respectively.
Paragraph 38 · 48% changed
Interest expense increased $0.8 million in 2024 is primarily from 2025, compared to the same period of 2024. Interest expense includes contractual coupon interest on our outstanding convertible notes and the convertible debt outstanding as of December 31, 2024. On December 14, 2023, we entered into a privately negotiated exchange and subscription agreement with certain holders associated accretion of the 2019 Notes and certain new investors pursuant to which we issued $600.0 million aggregate principal amount discount. The discount is being accreted into interest expense using the effective interest method over the term of the 2023 Notes. Interest expense in 2024 includes $0.1 million of interest on the 2019 Notes, compared to $1.0 million of interest expense on the 2019 Notes in 2023. Interest expense in 2024 also includes $6.0 million of contractual coupon interest on the 2023 Notes for which there were no comparable amounts in 2023 as well as $13.7 million in accretion of the $82.1 million debt discount on the modified notes, which includes the accretion of an increase in principal and the accretion of increased fair value of the conversion option in 2024, for which there were no comparable costs in 2023. defined below. See Note 15, 13, “Convertible Senior Notes,” Notes” in the notes to our the consolidated financial statements statements, included within Part IV, Item 15, “Exhibits and Financial Statement Schedules”, in this report Annual Report on Form 10-K for more information on this transaction. detail.
Paragraph 43 · 48% changed
For year ended December 31, 2024, we recorded an income tax benefit of $1.5 million. The effective tax rate was 5.6% for 2024 and is based upon the net loss for the year ended December 31, 2024 and the composition of income in different jurisdictions. The difference in effective tax rates between 2024 and 2023 the periods was primarily due to a loss the increase in income before income taxes taxes, nontaxable contingent consideration, lower nondeductible stock-based compensation and nonrecurring nondeductible loss on extinguishment an increase in valuation allowance offset by stock windfall tax benefits. Our effective tax rate for the year ended December 31, 2025 was more than the U.S. statutory rate of debt 21% primarily due to an increase in valuation allowance offset by nontaxable contingent consideration and debt discount that occurred in 2023. stock windfall tax benefits.
Paragraph 35 · 47% changed
In 2025, SG&A costs increased by $44.8 $27.1 million, or 20.5%, in 2024, as 10.3%, compared to 2023 2024. The increase in SG&A is primarily due driven by an investment in personnel costs to $22.4 million in costs support growth, increased headcount, and incremental professional services, primarily driven by our acquisition and integration activities. These increases were partially offset by the incremental stock-based compensation expense incurred during 2024 associated with the modification of our former Chief Executive Officer’s (“CEO”) unvested equity awards resulting from the announcement of his in connection with their transition from CEO to Executive Chair of our Board, which was announced on June 12, 2024 Board of Directors. See Note 11, “Stockholders' Equity” included within Item 15, “Exhibits and effective September 1, 2024. For more information on the former CEO’s transition to Executive Chair of our Board, see Note 13, “Stockholders’ Equity - Chief Executive Officer Accounting Modifications” included Financial Statement Schedules”, in this report. In addition, employee-related costs increased $15.9 million, and rent increased $5.9 million primarily related to the expansion of our Waltham headquarters. Annual Report on Form 10-K for more information.
Paragraph 53 · 47% changed
Our investing activities consumed $123.3 $298.5 million of cash in 2023, 2025, primarily due to $186.6 $200.3 million in cash (net of cash received) used for the 2023 acquisitions purchase of Metenova marketable securities and FlexBiosys, in $70.3 million, net of cash acquired, primarily used for the aggregate. acquisition of the 908 Devices PAT Portfolio. Capital expenditures during 2025 consumed $39.0 $25.7 million, inclusive of $2.2 million in 2023, as we continue to increase our manufacturing capacity worldwide. Of these expenditures, $2.8 million represented of capitalized costs related to our internal-use software for 2023. These uses of cash were partially offset by the maturity of our short-term investment in U.S. treasury securities in June 2023, which provided cash of $102.3 million. software.
Paragraph 21 · 46% changed
The following discussion of the financial condition and results of operations should be read in conjunction with the accompanying consolidated financial statements and the related footnotes thereto. footnotes, included within Part IV, Item 15, “Exhibits and Financial Statement Schedules”, in this Annual Report on Form 10-K. All dollar and percentage changes made herein refer to the year ended December 31, 2025, compared with the year ended December 31, 2024, unless otherwise noted.
Paragraph 20 · 46% changed
See For more information about recent accounting pronouncements, refer to Note 2, “Summary of Significant Accounting Policies – Recent Accounting Standards Updates,” to our consolidated financial statements Policies”, included within Part IV, Item 15, “Exhibits and Financial Statement Schedules”, in this report for more information. Annual Report on Form 10-K.
Paragraph 9 · 45% changed
While The preparation of our significant financial statements and related disclosures require us to make estimates, assumptions and judgments. We believe the accounting policies are more fully described in below, some of which require estimates, assumptions and judgments, have the notes to our consolidated financial statements, we have identified the policies and estimates below as being critical to our business operations and the understanding of our results of operations. These policies require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The greatest potential impact of and any associated risks related to these policies on our business operations are discussed throughout “Management’s Discussion financial statements and Analysis of Financial Condition and Results of Operations,” specifically in the “Results of Operations” section, where such policies affect related disclosures. Therefore we consider these to be our reported and expected financial results. critical accounting policies. Although we believe that our estimates, assumptions, and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments, or conditions. See Note 2, “Summary of Significant Accounting Policies” in the notes to the consolidated financial statements, included within Part IV, Item 15, “Exhibits and Financial Statement Schedules”, in this Annual Report on Form 10-K.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors366 words changed in this paragraph; it is 37% similar to last year's version.
We may plan to build and integrate AI into our business practices, and the evolving nature of AI technologies and the surrounding legal and regulatory environment presents risks and uncertainties that could affect our business. The use of AI technology can give rise to intellectual property risks, including compromises to the disclosure or compromise of our confidential information or other proprietary intellectual property through the use of generative artificial intelligence tools. AI could also pose cybersecurity, data privacy, IT, regulatory, legal, operational, competitive, reputational, and intellectual property infringement. other risks and challenges that could affect our business. Specifically, risks related to bias, AI hallucinations, discrimination, harmful content, misinformation, fraud, scams, targeted attacks such as model poisoning or data poisoning, surveillance, data leakage, loss of consensus reality, inequality, environmental harms, and other harms may flow from our development, use, or deployment of AI technologies. Additionally, we expect to see increasing government regulation related to artificial intelligence use and ethics, which may also significantly increase the burden and cost of research, development and compliance in this area. For example, in the U.S., a number of states have proposed and or passed dozens of laws over the past year regulating various uses and applications of AI, AI and federal regulators have issued guidance affecting the use AI governance, including addressing deployment of AI in regulated sectors. In Europe, healthcare settings. At the EU’s Artificial Intelligence Act (“AI Act”) - which entered into force federal level, the Trump Administration has endorsed a federal moratorium on August 1, 2024 and, with some exceptions, will begin to apply as enforcement of August 2, 2026 - imposes significant obligations on providers and deployers of high-risk artificial intelligence systems, and encourages providers and deployers of artificial intelligence systems to account for EU ethical principles in their development and use of these systems. If we develop or deploy certain state-level AI systems that are governed by these laws and regulations, we may be required to adopt higher standards of data quality, transparency, and human oversight, and adhere to specific and potentially burdensome and costly ethical, accountability, and administrative requirements. Even in the absence of dedicate AI laws and regulations, we may be subject to novel legal and business risks relating to our adoption of these new technologies. Our vendors may in turn incorporate AI tools into their own offerings, and the providers of these AI tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving the theft and misuse of personal information, confidential information, and intellectual property. Any of these outcomes could damage our reputation, result in the loss of valuable property and information, and adversely impact our business. regulation,

Source: Item 1A, 10-K 0001193125-26-076528 vs Item 1A, 10-K 0000950170-25-038999

MD&A219 words changed in this paragraph; it is 52% similar to last year's version.
Total consideration transferred for acquisitions is allocated to the tangible and intangible assets acquired and liabilities assumed, if any, based on their fair values at the dates of acquisition. This purchase price allocation process requires management to make significant estimates and assumptions with respect to intangible assets. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions determined by management. Any excess of purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as any contingent consideration, where applicable, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of comprehensive income. The Company estimates the fair value of the contingent consideration earnouts using a Monte Carlo Simulation and updates the fair value of the contingent consideration at each reporting period based on the estimated probability of achieving the earnout targets and applying a discount rate that captures the risk associated with the expected contingent payments. To the extent that our estimates change in the future regarding the likelihood of achieving these targets, we may need to record material adjustments to our accrued contingent consideration. Such changes in the fair value of contingent consideration are recorded as contingent consideration in our consolidated statements of comprehensive income. The fair value of contingent consideration obligations for the year ended December 31, 2024 had a net change of $3.2 million primarily related to the change in the contingent consideration obligations from the acquisition of Avitide, Inc. (“Avitide”) in September 2021. income or loss.

Source: Item 7, 10-K 0001193125-26-076528 vs Item 7, 10-K 0000950170-25-038999

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of RGEN's Risk Factors and MD&A, 10-K Feb 26, 2026 against 10-K Mar 14, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
As part of our growth strategy, we may enter into strategic investments, collaborations, joint ventures, and similar arrangements to expand our capabilities, access new technologies and enter new markets. These transactions involve significant risks and uncertainties that could adversely affect our business, financial condition, or results of operations, including:
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•Limited Control and Alignment Challenges: In joint ventures or minority investments, we may have limited ability to influence strategic decisions or operational practices. Differences in objectives, governance structures, or priorities with partners can lead to conflicts and inefficiencies.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•Financial Exposure: Investments and collaborations may underperform or fail, resulting in impairment charges or loss of invested capital. Returns may be delayed, uncertain, or significantly below expectations.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•Dependence on Third Parties: Our success often depends on the performance and cooperation of partners for development, commercialization, or distribution activities. Delays, quality issues, or regulatory non-compliance by partners could negatively impact our operations.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•Intellectual Property Risks: Disputes over ownership or use of intellectual property, limitations on our ability to protect or enforce rights, and potential loss of proprietary technology through licensing arrangements.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•Operational and Compliance Risks: Challenges in monitoring and managing joint venture activities, exposure to unfamiliar legal, tax, and regulatory frameworks—particularly in foreign jurisdictions—and potential liability for actions taken by partners or affiliates.
Read it in 10-K Feb 26, 2026 at sec.gov
Show the other 68
AddedRisk Factors
•Termination or Non-Performance: Collaborations or joint ventures may be terminated early or fail to deliver anticipated benefits, leaving us without expected products, technologies, or revenue streams.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
There can be no assurance that any strategic investment, collaboration, or joint venture will achieve its intended objectives or generate anticipated benefits within a reasonable timeframe, or at all. Failure to successfully manage these risks could materially and adversely affect our business and growth prospects.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
To mitigate these risks, we have implemented strategies to reduce tariff exposure and closely monitor trade policy developments. However, recent litigation challenging the legality of certain tariffs before the U.S. Supreme Court introduces additional uncertainty. If such tariffs are deemed unlawful, resulting policy reversals or retaliatory measures could create new risks and volatility in global trade, which may adversely affect our operations and financial results.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedRisk Factors
Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately liquidity may exceed the capacity of such program. Additionally, there is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.
Read it in 10-K Mar 14, 2025 at sec.gov
RemovedRisk Factors
Following identification of these material weaknesses, and as part of our commitment to strengthen our internal control over financial reporting, we are implementing remedial actions under the oversight of the Audit Committee of our Board to address these deficiencies. Our remediation activities will include the following:
Read it in 10-K Mar 14, 2025 at sec.gov
RemovedRisk Factors
• Designing and implementing new internal controls to validate there is a complete listing of revenue contracts that have non-standard terms, which require incremental accounting analysis under ASC 606.
Read it in 10-K Mar 14, 2025 at sec.gov
RemovedRisk Factors
• Enhancing and expanding our existing revenue recognition control procedures and attributes when evaluating the accounting impact of non-standard contract terms and contract modifications.
Read it in 10-K Mar 14, 2025 at sec.gov
RemovedRisk Factors
• Increased education for internal resources on accounting for contracts within the scope of ASC 606 and deploying enablers to facilitate documentation of accounting analyses and conclusions.
Read it in 10-K Mar 14, 2025 at sec.gov
RewordedRisk Factors
In Europe, As currently enacted, the AI Act, which may now be amended as part of the EU’s Artificial Intelligence Act (“AI Act”) - which entered into force on August 1, 2024 and, with some exceptions, will begin to apply as of August 2, 2026 - Digital Omnibus imposes significant obligations on providers and deployers of high-risk artificial intelligence systems, and encourages providers and deployers of artificial intelligence systems to account for EU ethical principles in their development and use of these systems.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We Though we continue to actively and selectively pursue patent protection and seek to expand our patent estate, particularly for our products currently in development, and protection, we cannot be sure guarantee that any patent applications that we will file in the future or that any currently pending applications will issue on a timely basis, if ever.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
These In addition, we face physical risks include risks to our manufacturing and supply chain from associated with climate change, including flooding, severe storms, wildfires, droughts or droughts, and extreme temperatures, all of which could disrupt manufacturing and supply chains, increase costs costs, and impair our ability to meet customer demands in a timely manner. demand.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We are subject to data privacy and protection security laws and regulations in various jurisdictions that apply to the collection, transmission, storage storage, security and use of proprietary information and personally-identifying information, personal data, which among other things, imposes certain requirements relating to the privacy, security and transmission of certain individually identifiable information. impose significant compliance obligations.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Specifically, Legislative and regulatory proposals in both the United States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals abroad continue to change the seek changes to health care system in ways systems that could affect our ability to sell our products profitably.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including imposing special requirements in respect of the processing of health and other sensitive data, requiring that consent of individuals to whom the personal data relates is obtained in certain circumstances, requiring additional disclosures to individuals regarding data processing activities, requiring that safeguards are implemented to protect the security and confidentiality of personal data, limiting retention periods for personal data, creating mandatory data breach notification requirements in certain circumstances, and requiring that certain measures (including contractual requirements) are put in place when engaging third-party service providers.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Patents that may be granted to us in Relatedly, certain foreign countries patent applications may be subject to opposition proceedings brought by third parties or result in suits by us, parties, which may be costly and result in adverse consequences for us.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Our acquisitions strategic investments, collaborations and joint ventures with and into business expose us to risks that could adversely affect our business, and we may not achieve the anticipated benefits of acquisitions of such investments, collaborations and/or joint ventures with or into such businesses or technologies. technologies
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
As a result of Based on these unremediated material weaknesses, our the Company’s management concluded that our at December 31, 2025, the Company’s internal control over financial reporting was not effective as of December 31, 2024. effective.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
In some cases, Though we are not currently involved in any ongoing litigation or other proceeding regarding intellectual property, litigation or other proceedings may be necessary to assert claims of infringement, infringement or misappropriation, to enforce patents issued to us or our licensors, to protect trade secrets, know-how or other intellectual property rights we own or to determine the scope and validity of the proprietary rights of third parties.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Furthermore, if any of our current or future products compete with those of any of our largest customers, these customers may place fewer orders with us or cease placing orders with us, which would negatively affect our revenues and operating results.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
It is possible that stakeholders Stakeholders may not be satisfied with our ESG practices or the speed pace of their adoption, or that we may not sufficiently fail to communicate our ESG practices sufficiently to stakeholders. them effectively.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
Our Any future corporate restructuring and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our any future restructuring efforts due to unforeseen difficulties, delays or unexpected costs.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
A material cyber-attack or other security incident or compromise could cause interruptions in our operations and could result in a material disruption of our business operations, damage to our reputation or a loss of revenues.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
On March 4, 2025, the Company completed its acquisition of 908 Devices Inc.’s (“908 Devices”) desktop portfolio of four devices for bioprocessing process analytical technology applications (“PAT Portfolio”). In connection with the transaction, Repligen also acquired facilities, employees, equipment and lease obligations for facilities in North Carolina and Braunschweig, Germany as well as certain working capital balances related to the PAT Portfolio. This transaction is referred to as the 908 Devices PAT Portfolio acquisition.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
The addition of these desktop assets complements and strengthens Repligen’s differentiated PAT Portfolio that provides its biopharmaceutical and CDMO customers with actionable insights to optimize development processes and improve manufacturing efficiencies.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
A change in the estimated timing or amount of demand for our products could result in additional provisions for excess inventory quantities on hand. In addition, significant unanticipated changes in demand or unexpected quality failures could have a significant impact on the value of inventory and reported operating results.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
Fair value of contingent consideration includes estimates and judgments made by management regarding the probability that future contingent payments will be made and the extent of payments to be earned in excess of defined minimum sales thresholds and achievement of defined milestones. To the extent that our estimates change in the future regarding the likelihood of achieving these targets, we may need to record material adjustments to our accrued contingent consideration. Such changes in the fair value of contingent consideration are recorded as contingent consideration in our consolidated statements of comprehensive income or loss.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
In 2025, product revenue increased by $103.8 million, or 16.4% , compared to 2024. This growth is widespread across our portfolio of products and includes significant contributions from all our franchises. Geographically, product revenue increased 15.7% in North America, 16.0% in Europe and 19.3% in Asia Pacific and the rest of the world. Related to our acquisitions, products acquired from
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
In 2025, cost of goods sold decreased $7.8 million, or 2.2%, compared to 2024. The decrease in cost of goods sold is primarily due to lower costs related to scrap, excess and obsolete inventory and restructuring activities in 2025, compared to those incurred in 2024. Restructuring relates to activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations. These decreases were partially offset by higher export duties, direct material and labor costs.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
See Note 5, “Restructuring Activities and Other Inventory-Related Charges” in the notes to the consolidated financial statements, included within Part IV, Item 15, “Exhibits and Financial Statement Schedules”, in this Annual Report on Form 10-K, for more detail.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
On July 4, 2025, the United States enacted into law new tax legislation, the One Big Beautiful Bill Act (“OBBBA”), which contains several provisions modifying the corporate income tax code such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, updates to the international tax framework and the reinstatement of certain business-related provisions. The legislation has multiple effective dates, with provisions taking effect from 2025 through 2027. The changes effective in 2025 are included in our provision for income taxes for the year ended December 31, 2025 and were not material. We do not expect the OBBBA to have a material impact on our consolidated financial statements or results of operations in future periods.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
See Note 10, “Income Taxes” in the notes to the consolidated financial statements, included within Part IV, Item 15, “Exhibits and Financial Statement Schedules”, in this Annual Report on Form 10-K for more detail.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedMD&A
When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. We do not assess whether a significant financing component exists if the period between when we perform our obligations under the contract and when the customer pays is one year or less. None of our contracts contained a significant financing component as of December 31, 2024.
Read it in 10-K Mar 14, 2025 at sec.gov
RemovedMD&A
Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. We determine standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, we estimate the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.
Read it in 10-K Mar 14, 2025 at sec.gov
RemovedMD&A
Shipping and handling fees are recorded as a component of product revenue, with the associated costs recorded as a component of cost of goods sold in our consolidated statements of comprehensive income.
Read it in 10-K Mar 14, 2025 at sec.gov
RemovedMD&A
A change in the estimated timing or amount of demand for our products could result in additional provisions for excess inventory quantities on hand. Any significant unanticipated changes in demand or unexpected quality failures could have a significant impact on the value of inventory and reported operating results. In 2024, we recorded $36.0 million in inventory adjustments, which includes the impact of the Company discontinuing the sale of certain product SKUs and the impact of having proactively secured materials during the pandemic to meet accelerated demand during a challenging supply chain environment in the industry. Where demand has reduced, finished goods and raw materials, whose value exceeded the projected requirements to be used before reaching their expiration date, or in a reasonable time horizon, were written down to their realizable value. The Restructuring Plan described in Note 7, “Restructuring Activities and Other Inventory-Related Charges,” to our consolidated financial statements, also includes the closing of manufacturing facilities and excess production lines, which included inventory that could not be repurposed.
Read it in 10-K Mar 14, 2025 at sec.gov
RemovedMD&A
We test goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that would indicate impairment and trigger an interim impairment assessment include, but are not limited to, macroeconomic conditions, industry and market conditions, entity specific factors such as strategies and financial performance, a significant adverse change in legal factors and an adverse action or assessment by a regulator. Goodwill is tested for impairment as of October 1 of each year, or more frequently as warranted by events or changes in circumstances mentioned above. Accounting guidance also permits an optional qualitative assessment for goodwill to
Read it in 10-K Mar 14, 2025 at sec.gov
RemovedMD&A
determine whether it is more likely than not that the carrying value of a reporting unit exceeds its fair value. If, after this qualitative assessment, we determine that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then no further quantitative testing would be necessary. A quantitative assessment is performed if the qualitative assessment results in a more likely than not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the reporting unit’s carrying value exceeds its fair value.
Read it in 10-K Mar 14, 2025 at sec.gov
RemovedMD&A
We operate as one reporting unit. We performed a qualitative assessment for our reporting unit as of October 1, 2024, December 31, 2023 and December 31, 2022. Based on the assessment, we concluded that it was more likely than not that the estimated fair value of our reporting unit for 2024, 2023 and 2022 was higher than its carrying value for such years, and that the performance of the quantitative impairment test was not required. Therefore, no impairment was required for any of the periods presented.
Read it in 10-K Mar 14, 2025 at sec.gov
RemovedMD&A
Prior to fiscal year 2024, testing of impairment on our goodwill occurred annually as of our measurement date of December 31st, pursuant to Company policy. Subsequent to the 2023 annual impairment test, which was completed on December 31, 2023, we voluntarily changed our annual impairment assessment date from December 31st to October 1st, the first day of our fourth quarter, beginning on October 1, 2024. The change is being made to better align the annual impairment assessment date with our annual planning and budgeting process as well as the long-term planning and forecasting process. We have determined that this voluntary change in accounting principle is preferable and will not impact our consolidated financial statements nor is it being done to accelerate, avoid or trigger an impairment charge. This change is not going to be applied retrospectively as it is impracticable to do so because retrospective application would require application of significant estimates and assumptions with the use of hindsight. Therefore, the change will be applied prospectively.
Read it in 10-K Mar 14, 2025 at sec.gov
RemovedMD&A
We evaluated the Exchange Transaction and determined approximately $29.6 million of the $217.7 million principal of the exchanged 2019 Notes were accounted for as extinguishments of debt and approximately $188.1 million were accounted for as modification of debt. As a result, we recognized a $12.7 million loss on extinguishment of debt in our consolidated statements of comprehensive income for the year ended December 31, 2023. This included unamortized debt issuance costs related to the extinguished 2019 Notes. Under modification accounting, the carrying amount of the modified 2019 Notes was reduced by $2.8 million, with the offset going to additional paid-in capital, to account for the increase in fair value of the embedded conversion option in the modification. The increase in principal, along with the increased option value, totaling $82.1 million, is reflected as a debt discount and is a direct reduction from the carrying value of the debt on our consolidated balance sheets. This amount will be accreted as an adjustment to interest expense using the effective interest method and will accrete up to the full face value of the 2023 Notes of $600.0 million.
Read it in 10-K Mar 14, 2025 at sec.gov
RemovedMD&A
Proceeds from the Subscription Transactions amounted to $276.1 million after debt issuance costs of $14.0 million. The exchange resulted in $6.2 million of the debt issuance costs related to the modified notes to be recorded to amortization of debt issuance costs in our 2023 consolidated statement of comprehensive income under the rules of modification accounting. The remaining debt issuance costs of $7.8 million as well as $0.7 million of unamortized costs carried over from the 2019 Notes at the exchange date, were capitalized within long-term debt (as a contra-liability) in our consolidated balance sheets and will be amortized as an adjustment to amortization of debt issuance costs over the five-year term of the 2023 Notes in our consolidated statement of comprehensive income. The carrying value of the 2023 Notes of $525.6 million is included in long-term debt on our consolidated balance sheets as of December 31, 2024.
Read it in 10-K Mar 14, 2025 at sec.gov
RemovedMD&A
Prior to the close of business on the business day immediately preceding September 15, 2028, the 2023 Notes will be convertible at the option of the holders of 2023 Notes only upon the satisfaction of specified conditions and during certain periods into cash up to their principal amount, and into cash, shares of the Company's common stock or a combination of cash and the Company's common stock, at the Company's election, for the conversion value above the principal amount, if any. Thereafter until the close of business on the second scheduled trading day immediately preceding the maturity date, the 2023 Notes will be convertible at the options of the holders of 2023 Notes at any time regardless of these conditions. The Company may redeem for cash, all or a portion of the 2023 Notes, at its option, on or after December 18, 2026 and prior to the 21st scheduled trading day immediately preceding the maturity date at a redemption price of 100% of the principal amount of the 2023 Notes to be redeemed, plus accrued and unpaid interest to, but excluding the redemption date, if certain conditions are met in accordance to the indenture.
Read it in 10-K Mar 14, 2025 at sec.gov
RewordedMD&A
Information pertaining to fiscal years 2024 and 2023 and 2022 was included in the Company’s Annual Report on Form 10-K/A (“Form 10-K/A”) 10-K for the year ended December 31, 2023, 2024, on pages 36 39 through 50 52 under Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which was filed with the Securities and Exchange Commission SEC on November 18, 2024 and Form 10-K for the year ended December 31, 2022, on pages 37 through 53 under Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which was filed with the Securities and Exchange Commission on February 22, 2023, respectively. March 14, 2025.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
For 2024, 2025, our operating activities provided cash of $175.4 $117.4 million reflecting net loss income of $25.5 $48.9 million and non-cash charges totaling $140.0 $119.4 million primarily related to depreciation, intangible depreciation and amortization, stock-based compensation, right of use asset amortization, amortization of debt discount and issuance costs, contingent consideration fair value adjustments, net unrealized foreign exchange gains and deferred income taxes, stock-based compensation charges, loss on disposal of fixed assets, and right of use asset amortization. taxes.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Our investing activities consumed $123.3 $298.5 million of cash in 2023, 2025, primarily due to $186.6 $200.3 million in cash (net of cash received) used for the 2023 acquisitions purchase of Metenova marketable securities and FlexBiosys, in $70.3 million, net of cash acquired, primarily used for the aggregate. acquisition of the 908 Devices PAT Portfolio.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
See Note 15, 13, “Convertible Senior Notes,” Notes” in the notes to our the consolidated financial statements statements, included within Part IV, Item 15, “Exhibits and Financial Statement Schedules”, in this report Annual Report on Form 10-K for more information on this transaction. detail.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
We believe The Company believes the estimated purchased customer relationships, developed technologies, trademark/tradename, patents, non-competition agreements trademark/tradename and in-process research and development ("R&D") amounts so determined other intangible assets identified in its acquisitions represent the fair value at the date of acquisition acquisition, and do not exceed the amount a third-party would pay for the such assets.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
For the Years Year Ended December 31, 2025 2024 vs 2023 2024 2023 $ Change % Change (Amounts in thousands, except for percentage data) thousands) Income tax provision (benefit) provision $ 13,489 $ (1,521) $ 21,111 $ (22,632) (107.2 $15,010 (986.9 Effective tax rate 21.6% 5.6% 37.2%
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Accounts These unfavorable changes in working capital were partially offset by increases in accounts payable and other accrued expenses provided $19.0 million liabilities of $6.0 million, due to the timing of in payments to vendors.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
These direct sales have represented 90.8% of our total product revenue during 2025 compared to 89.7% of our total product revenue during 2024 compared to 85.8% of our total product revenue in 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
For the Years Year Ended December 31, 2025 2024 2023 (Amounts in thousands) Filtration products $ 402,792 $ 372,963 $ 341,379 Chromatography products 153,176 122,810 126,629 Process analytics products 81,237 59,301 56,820 Proteins products 97,435 74,425 103,463 Other 3,320 4,679 3,688 Total product revenue $ 737,960 $ 634,178 $ 631,979
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
We are subject to a territorial tax system under the Tax Cuts and Jobs Act enacted in December 2017, in which we are required to provide for tax on Global Intangible Low-Taxed Income (“GILTI”) earned by certain foreign subsidiaries.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The following discussion of the financial condition and results of operations should be read in conjunction with the accompanying consolidated financial statements and the related footnotes thereto. footnotes, included within Part IV, Item 15, “Exhibits and Financial Statement Schedules”, in this Annual Report on Form 10-K.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Since 2016, we have been increasingly We are continuously focused on selling our products directly to customers in the life sciences and pharmaceutical industry and to our contract manufacturers. industries, including CDMOs.
Read it in 10-K Feb 26, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RGEN/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.